Results 101 to 110 of about 1,506 (115)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

Annals of Oncology, 2021
Blaine Mooers, Jie Wu, Vivek Subbiah
exaly  

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial☆

Annals of Oncology, 2022
S Kong, D W Bowles, J F Gainor
exaly  

ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib

Pharmacological Research, 2021
Rolf W Sparidans, Alfred H Schinkel, Jos Beijnen   +2 more
exaly  

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience

European Journal of Cancer, 2021
Sehhoon Park, Jong-Mu Sun, Yeonghee Eun
exaly  

An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)

Journal of Oncology Pharmacy Practice, 2023
Marc Geirnaert
exaly  

Review of Synthetic Routes and Crystalline Forms of the Oncology Drugs Capmatinib, Selpercatinib, and Pralsetinib

Organic Process Research and Development, 2021
David Hughes
exaly  

Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib

Clinical Lung Cancer, 2022
Justin M Honce, Tejas Patil, David Chun Cheong Tsui   +2 more
exaly  

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect

International Journal of Molecular Sciences, 2023
Michael C Kreissl, Daniela Grimm, Markus Wehland   +2 more
exaly  

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer

Supportive Care in Cancer, 2023
Xiaotao Zhang, Xuejiao Yang
exaly